Immunosuppressants drugs - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.77 [0.43, 1.40]< 10%2 studies (2/-)80.4 %some concernnot evaluable moderatecrucial-
deaths 0.68 [0.48, 0.97]< 10%5 studies (5/-)98.4 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.70 [0.40, 1.21]< 10%1 study (1/-)89.9 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.53 [0.22, 1.28]< 178%2 studies (2/-)92.0 %some concernnot evaluable moderateimportant-
clinical improvement 1.39 [0.76, 2.54]> 10%1 study (1/-)85.8 %some concernnot evaluable moderateimportant-
death or ventilation 0.79 [0.53, 1.16]< 140%2 studies (2/-)88.6 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.47 [0.03, 7.48]< 10%1 study (1/-)70.4 %lownot evaluable highimportant-

safety endpoints 00

serious adverse events 0.73 [0.45, 1.19]< 10%1 study (1/-)89.7 %some concernnot evaluable moderateimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.